세계의 질용 항진균제 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Vaginal Antifungals Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

US $ 4,995 ￦ 6,970,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,179,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,853,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 세계의 질용 항진균제 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 성장 촉진요인, 동향, 기회 및 과제를 포함한 중요한 시장 역학을 철저히 평가하고 시장 구조에 대한 자세한 인사이트를 제공합니다.

주요 인사이트

• 질용 항진균제 시장 규모(2024년) : 11억 달러
• 시장 예측치(2032년) : 14억 달러
• 세계 시장 성장률(CAGR 2024-2032년) : 2.7%

질용 항진균제 시장 : 조사 범위

질용 항진균제는 질 영역을 침범하는 칸디다증을 포함한 진균 감염의 치료에 필수적입니다. 이 약은 크림, 좌약, 정제, 연고 등 다양한 형태가 있으며 환자의 요구와 기호에 맞게 조정됩니다. 질용 항진균제 시장은 약국, 병원, 클리닉, 온라인 소매에 대응하고 증상을 완화하고 감염을 효과적으로 제거하는 광범위한 치료 옵션을 제공합니다. 시장 성장의 원동력은 여성의 건강 문제에 대한 의식 증가, 곰팡이 감염의 유병률 증가, 효능 및 환자의 편안함을 향상시키는 항진균 제제의 진보입니다.

시장 성장 촉진요인 :

세계의 질용 항진균제 시장은 질 진균 감염을 신속하고 효과적으로 치료하는 중요성에 대한 인식 증가와 같은 몇 가지 중요한 요인에 의해 추진되고 있습니다. 특히 습도가 높고 위생습관이 나쁜 지역에서의 칸디다증 이환율의 상승이 시장 확대를 더욱 뒷받침하고 있습니다. 새로운 제형 및 약물 전달 시스템 개발과 같은 기술의 진보는 치료 결과를 개선하고 부작용을 줄이고 시장 성장을 가속합니다. 게다가, 일반용 의약품(OTC) 항진균제의 가용성 증가와 전자상거래 플랫폼의 확대는 시장 기업이 보다 폭넓은 소비자층에 도달할 수 있는 새로운 길을 만들어 내고 있습니다.

시장 성장 억제요인 :

유망한 성장이 예상되는 반면, 질용 항진균제 시장은 규제 준수, 약물 내성 및 항진균제의 장기간 사용과 관련된 부작용과 관련된 과제에 직면하고 있습니다. 항진균제의 제조, 판매 및 사용에 대한 엄격한 규정은 제조업체 및 건강 관리 제공업체에게 컴플라이언스 부담을 부과하여 시장 진입 장벽 및 운영 비용에 영향을 미칩니다. 또한, 약물 내성 진균의 출현과 항진균 치료의 잠재적인 부작용은 특히 의료 예산에 제약이 있는 신흥국에서 시장 침투의 과제가 되고 있습니다. 이러한 규제 및 임상 장벽을 다루기 위해서는 안전하고 효과적인 항진균제에 대한 접근을 촉진하기 위해 업계 이해관계자와 정책 입안자가 협력해야 합니다.

시장 기회 :

질용 항진균제 시장은 기술 혁신, 인구 동향, 진화하는 건강 관리 제공 모델을 통해 큰 성장 기회를 제공합니다. 원격 의료 플랫폼 및 모바일 건강 앱과 같은 디지털 건강 기술의 통합은 환자의 항진균 치료에 대한 액세스를 향상시키고 치료의 어드밴스와 결과를 향상시킵니다. 또한, 재발성 감염의 예방과 치료에 항진균제의 적용 확대가 시장 범위를 넓히고 기술 혁신을 자극하고 있습니다. 전략적 파트너십, 연구개발 투자, 사용자 친화적이고 비용 효율적인 항진균 솔루션 소개는 새로운 비즈니스 기회를 활용하고 역동적인 질용 항진균제 시장에서 리더십을 유지하는 데 필수적입니다.

이 보고서에서 다루는 주요 질문

• 세계 질용 항진균제 시장의 성장을 가속하는 주요 요인은 무엇인가?
• 다양한 헬스케어 장면에서 항진균제의 채용을 촉진하고 있는 제품 유형 및 용도는 무엇인가?
• 기술의 진보는 질용 항진균제 시장 경쟁 구도를 어떻게 바꾸고 있는가?
• 질용 항진균제 시장에 기여하는 주요 기업은 어디서 시장의 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계의 질용 항진균제 시장에서의 새로운 동향 및 장래성은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위 및 분류
• 시장의 정의, 범위 및 제한
• 포함 및 제외

제3장 주요 시장 동향

• 시장에 영향을 주는 주요 동향
• 주요 혁신 및 개발 동향

제4장 주요 성공 요인

• 주요 제조업체에 의한 프로모션 전략
• 주요 규제
• 환급 시나리오
• 파이프라인 분석
• 밸류체인 분석
• PESTEL 분석
• Porter's Five Forces 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 : 관련성 및 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 약별별
  • 투여 경로별
  • 유통 채널별
  • 국가별
• 시장 시나리오(2024년)

제7장 세계의 질용 항진균제 시장 수요 분석

• 과거 시장 매출 분석(2019-2023년)
• 현재 및 장래 시장 매출 예측(2024-2032년)
  • 전년대비 성장 동향 분석
  • 절대액의 기회

제8장 세계의 질용 항진균제 시장 분석 : 약제별

• 서문 : 주요 조사 결과
• 과거 시장 규모 분석 : 약제별(2019-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 약제별(2024-2032년)
  • 플루코나졸
  • 나이스타틴
  • 플루시토신
  • 클로트리마졸
  • 케토코나졸
  • 테르비나핀
  • 기타
• 약제별 시장의 매력 분석

제9장 세계의 질용 항진균제 시장 분석 : 투여 경로별

• 서문 : 주요 조사 결과
• 과거 시장 규모 분석 : 투여 경로별(2019-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 투여 경로별(2024-2032년)
  • 경구
  • 국소
• 투여 경로별 시장의 매력 분석

제10장 세계의 질용 항진균제 시장 분석 : 유통 채널별

• 서문 : 주요 조사 결과
• 과거 시장 규모 분석 : 유통 채널별(2019-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 유통 채널별(2024-2032년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국
• 유통 채널별 시장의 매력 분석

제11장 세계의 질용 항진균제 시장 분석 : 지역별

• 서문 : 주요 조사 결과
• 과거 시장 규모 분석 : 지역별(2019-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 지역별(2024-2032년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카
• 지역별 시장의 매력 분석

제12장 북미의 질용 항진균제 시장 분석

제13장 라틴아메리카의 질용 항진균제 시장 분석

제14장 유럽의 질용 항진균제 시장 분석

제15장 동아시아의 질용 항진균제 시장 분석

제16장 남아시아의 질용 항진균제 시장 분석

제17장 오세아니아의 질용 항진균제 시장

제18장 중동 및 아프리카의 질용 항진균제 시장 분석

제19장 시장 구조 분석

• 기업계층별 시장 분석
• 시장 집중
• 주요 기업의 시장 점유율 분석
• 시장현재분석

제20장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁의 상세
  • Pfizer Inc.
  • Bausch Health Companies Inc
  • ANI Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Unique Pharmaceuticals
  • PEPTONIC medical AB
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories
  • SCYNEXIS, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, SA
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

제21장 전제 및 약어

제22장 조사 방법

AJY

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for vaginal antifungals. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Vaginal Antifungals Market Size (2024E): USD 1.1 Billion
• Projected Market Value (2032F): USD 1.4 Billion
• Global Market Growth Rate (CAGR 2024 to 2032): 2.7%

Vaginal Antifungals Market - Report Scope:

Vaginal antifungals are essential in the treatment of fungal infections, including candidiasis, that affect the vaginal area. These medications come in various forms, such as creams, suppositories, tablets, and ointments, tailored to different patient needs and preferences. The vaginal antifungals market caters to pharmacies, hospitals, clinics, and online retail, offering a range of treatment options to alleviate symptoms and eliminate infections effectively. Market growth is driven by increasing awareness of women's health issues, rising prevalence of fungal infections, and advancements in antifungal formulations enhancing efficacy and patient comfort.

Market Growth Drivers:

The global vaginal antifungals market is propelled by several key factors, including growing awareness about the importance of treating vaginal fungal infections promptly and effectively. The rising incidence of candidiasis, particularly in regions with high humidity and poor hygiene practices, further drives market expansion. Technological advancements, such as the development of novel drug formulations and delivery systems, offer improved treatment outcomes and reduced side effects, fostering market growth. Moreover, the increasing availability of over-the-counter (OTC) antifungal products and the expansion of e-commerce platforms create new avenues for market players to reach a broader consumer base.

Market Restraints:

Despite promising growth prospects, the vaginal antifungals market faces challenges related to regulatory compliance, drug resistance, and side effects associated with prolonged antifungal use. Stringent regulations governing the manufacturing, marketing, and use of antifungal medications impose compliance burdens on manufacturers and healthcare providers, affecting market entry barriers and operational costs. Furthermore, the emergence of drug-resistant fungal strains and the potential side effects of antifungal treatments pose challenges for market penetration, particularly in emerging economies with constrained healthcare budgets. Addressing these regulatory and clinical barriers requires collaboration between industry stakeholders and policymakers to promote access to safe and effective antifungal solutions.

Market Opportunities:

The vaginal antifungals market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as telemedicine platforms and mobile health apps, enhances patient access to antifungal treatments and improves treatment adherence and outcomes. Furthermore, the expanding application of antifungals in preventing and treating recurrent infections broadens the market scope and stimulates innovation. Strategic partnerships, investment in research and development, and the introduction of user-friendly, cost-effective antifungal solutions are essential to capitalize on emerging opportunities and sustain market leadership in the dynamic vaginal antifungals landscape.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the vaginal antifungals market globally?
• Which product types and applications are driving antifungal adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the vaginal antifungals market?
• Who are the key players contributing to the vaginal antifungals market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global vaginal antifungals market?

Competitive Intelligence and Business Strategy:

Leading players in the global vaginal antifungals market, including Bayer AG, Pfizer Inc., and Johnson & Johnson, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced antifungal formulations, including combination therapies and extended-release formulations, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, pharmacies, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving antifungals landscape.

Key Companies Profiled:

• Pfizer Inc.
• Bausch Health Companies Inc
• ANI Pharmaceuticals, Inc.
• Hikma Pharmaceuticals Plc
• Lupin Limited
• Mycovia Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Unique Pharmaceuticals
• PEPTONIC Medical AB
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories
• SCYNEXIS, Inc.
• Basilea Pharmaceutica Ltd.
• Astellas Pharma Inc.
• Grupo Ferrer Internacional, S.A.
• Pacgen Life Science Corporation
• NovaDigm Therapeutics, Inc.
• Cidara Therapeutics, Inc.
• Amplyx Pharmaceuticals Inc.

Vaginal Antifungals Industry Research Segments

By Drug:

• Fluconazole
• Nystatin
• Flucytosine
• Clotrimazole
• Ketoconazole
• Terbinafine

By Route of Administration:

• Oral
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Key Innovation / Development Trends

4. Key Success Factors

• 4.1. Promotional Strategies, By Key Manufacturers
• 4.2. Key Regulations
• 4.3. Reimbursement Scenario
• 4.4. Pipeline Analysis
• 4.5. Value Chain Analysis
• 4.6. PESTEL Analysis
• 4.7. Porter's Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure Outlook
  • 5.1.3. Global Antifungal Drugs Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Impact of the COVID-19 Pandemic
  • 5.2.2. Increasing Product Launch Activities
  • 5.2.3. Prevalence of Vaginal Fungal Infections in HRT Patients
  • 5.2.4. High Rates of Vulvovaginal Candidiasis
  • 5.2.5. Impact on Quality-of-Life
  • 5.2.6. Increasing Number of People with Predisposing Conditions Such as Diabetes Treated with SGLT2 Inhibitors
  • 5.2.7. Growing Problems of Azole Resistance
  • 5.2.8. Toxicity of Antifungal Drugs
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Drug
  • 6.1.2. By Route of Administration
  • 6.1.3. By Distribution Channel
  • 6.1.4. By Country
• 6.2. 2024 Market Scenario

7. Global Vaginal Antifungals Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Drug

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Drug, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug, 2024-2032
  • 8.3.1. Fluconazole
  • 8.3.2. Nystatin
  • 8.3.3. Flucytosine
  • 8.3.4. Clotrimazole
  • 8.3.5. Ketoconazole
  • 8.3.6. Terbinafine
  • 8.3.7. Others
• 8.4. Market Attractiveness Analysis By Drug

9. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2024-2032
  • 9.3.1. Oral
  • 9.3.2. Topical
• 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2032
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Region

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2032
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. East Asia
  • 11.3.5. South Asia
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa
• 11.4. Market Attractiveness Analysis By Region

12. North America Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Drug
  • 12.3.3. By Route of Administration
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Drug
  • 12.4.3. By Route of Administration
  • 12.4.4. By Distribution Channel
• 12.5. Market Trends
• 12.6. Key Market Participants - Intensity Mapping
• 12.7. Drivers and Restraints - Impact Analysis
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. U.S. Vaginal Antifungals Market Analysis
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 12.8.1.2.1. By Drug
      • 12.8.1.2.2. By Route of Administration
      • 12.8.1.2.3. By Distribution Channel
  • 12.8.2. Canada Vaginal Antifungals Market Analysis
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 12.8.2.2.1. By Drug
      • 12.8.2.2.2. By Route of Administration
      • 12.8.2.2.3. By Distribution Channel

13. Latin America Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. Mexico
    • 13.3.1.2. Brazil
    • 13.3.1.3. Argentina
    • 13.3.1.4. Rest of Latin America
      • 13.3.1.4.1. By Country
      • 13.3.1.4.2. By Drug
      • 13.3.1.4.3. By Route of Administration
      • 13.3.1.4.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug
  • 13.4.3. By Route of Administration
  • 13.4.4. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Mexico Vaginal Antifungals Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.1.2.1. By Drug
      • 13.8.1.2.2. By Route of Administration
      • 13.8.1.2.3. By Distribution Channel
  • 13.8.2. Brazil Vaginal Antifungals Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.2.2.1. By Country
      • 13.8.2.2.2. By Drug
      • 13.8.2.2.3. By Route of Administration
      • 13.8.2.2.4. By Distribution Channel
  • 13.8.3. Argentina Vaginal Antifungals Market Analysis
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.3.2.1. By Drug
      • 13.8.3.2.2. By Route of Administration
      • 13.8.3.2.3. By Distribution Channel

14. Europe Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. Germany
    • 14.3.1.2. Italy
    • 14.3.1.3. France
    • 14.3.1.4. U.K.
    • 14.3.1.5. Spain
    • 14.3.1.6. BENELUX
    • 14.3.1.7. Russia
    • 14.3.1.8. Rest of Europe
  • 14.3.2. By Drug
  • 14.3.3. By Route of Administration
  • 14.3.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug
  • 14.4.3. By Route of Administration
  • 14.4.4. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Germany Vaginal Antifungals Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.1.2.1. By Drug
      • 14.8.1.2.2. By Route of Administration
      • 14.8.1.2.3. By Distribution Channel
  • 14.8.2. Italy Vaginal Antifungals Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.2.2.1. By Drug
      • 14.8.2.2.2. By Route of Administration
      • 14.8.2.2.3. By Distribution Channel
  • 14.8.3. France Vaginal Antifungals Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.3.2.1. By Drug
      • 14.8.3.2.2. By Route of Administration
      • 14.8.3.2.3. By Distribution Channel
  • 14.8.4. U.K. Vaginal Antifungals Market Analysis
    • 14.8.4.1. Introduction
    • 14.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.4.2.1. By Drug
      • 14.8.4.2.2. By Route of Administration
      • 14.8.4.2.3. By Distribution Channel
  • 14.8.5. Spain Vaginal Antifungals Market Analysis
    • 14.8.5.1. Introduction
    • 14.8.5.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.5.2.1. By Drug
      • 14.8.5.2.2. By Route of Administration
      • 14.8.5.2.3. By Distribution Channel
  • 14.8.6. BENELUX Vaginal Antifungals Market Analysis
    • 14.8.6.1. Introduction
    • 14.8.6.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.6.2.1. By Drug
      • 14.8.6.2.2. By Route of Administration
      • 14.8.6.2.3. By Distribution Channel
  • 14.8.7. Russia Vaginal Antifungals Market Analysis
    • 14.8.7.1. Introduction
    • 14.8.7.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.7.2.1. By Drug
      • 14.8.7.2.2. By Route of Administration
      • 14.8.7.2.3. By Distribution Channel

15. East Asia Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Drug
  • 15.3.3. By Route of Administration
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug
  • 15.4.3. By Route of Administration
  • 15.4.4. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. China Vaginal Antifungals Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.1.2.1. By Drug
      • 15.8.1.2.2. By Route of Administration
      • 15.8.1.2.3. By Distribution Channel
  • 15.8.2. Japan Vaginal Antifungals Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.2.2.1. By Drug
      • 15.8.2.2.2. By Route of Administration
      • 15.8.2.2.3. By Distribution Channel
  • 15.8.3. South Korea Vaginal Antifungals Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.3.2.1. By Drug
      • 15.8.3.2.2. By Route of Administration
      • 15.8.3.2.3. By Distribution Channel

16. South Asia Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Thailand
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Drug
  • 16.3.3. By Route of Administration
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug
  • 16.4.3. By Route of Administration
  • 16.4.4. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Vaginal Antifungals Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.1.2.1. By Drug
      • 16.8.1.2.2. By Route of Administration
      • 16.8.1.2.3. By Distribution Channel
  • 16.8.2. Indonesia Vaginal Antifungals Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.2.2.1. By Drug
      • 16.8.2.2.2. By Route of Administration
      • 16.8.2.2.3. By Distribution Channel
  • 16.8.3. Malaysia Vaginal Antifungals Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.3.2.1. By Drug
      • 16.8.3.2.2. By Route of Administration
      • 16.8.3.2.3. By Distribution Channel
  • 16.8.4. Thailand Vaginal Antifungals Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.4.2.1. By Drug
      • 16.8.4.2.2. By Route of Administration
      • 16.8.4.2.3. By Distribution Channel

17. Oceania Vaginal Antifungals Market 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. Australia
    • 17.3.1.2. New Zealand
  • 17.3.2. By Drug
  • 17.3.3. By Route of Administration
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug
  • 17.4.3. By Route of Administration
  • 17.4.4. By Distribution Channel
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Country Level Analysis & Forecast
  • 17.7.1. Australia Vaginal Antifungals Market Analysis
    • 17.7.1.1. Introduction
    • 17.7.1.2. Market Analysis and Forecast By Market Taxonomy
      • 17.7.1.2.1. By Drug
      • 17.7.1.2.2. By Route of Administration
      • 17.7.1.2.3. By Distribution Channel
  • 17.7.2. New Zealand Vaginal Antifungals Market Analysis
    • 17.7.2.1. Introduction
    • 17.7.2.2. Market Analysis and Forecast By Market Taxonomy
      • 17.7.2.2.1. By Drug
      • 17.7.2.2.2. By Route of Administration
      • 17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
  • 18.3.1. By Country
    • 18.3.1.1. GCC Countries
    • 18.3.1.2. Turkey
    • 18.3.1.3. South Africa
    • 18.3.1.4. North Africa
    • 18.3.1.5. Rest of Middle East and Africa
  • 18.3.2. By Drug
  • 18.3.3. By Route of Administration
  • 18.3.4. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug
  • 18.4.3. By Route of Administration
  • 18.4.4. By Distribution Channel
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. GCC Countries Vaginal Antifungals Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.1.2.1. By Drug
      • 18.8.1.2.2. By Route of Administration
      • 18.8.1.2.3. By Distribution Channel
  • 18.8.2. Turkey Vaginal Antifungals Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.2.2.1. By Drug
      • 18.8.2.2.2. By Route of Administration
      • 18.8.2.2.3. By Distribution Channel
  • 18.8.3. South Africa Vaginal Antifungals Market Analysis
    • 18.8.3.1. Introduction
    • 18.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.3.2.1. By Drug
      • 18.8.3.2.2. By Route of Administration
      • 18.8.3.2.3. By Distribution Channel
  • 18.8.4. North Africa Vaginal Antifungals Market Analysis
    • 18.8.4.1. Introduction
    • 18.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.4.2.1. By Drug
      • 18.8.4.2.2. By Route of Administration
      • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

• 19.1. Market Analysis By Tier of Companies
• 19.2. Market Concentration
• 19.3. Market Share Analysis of Top Players
• 19.4. Market Presence Analysis

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Competition Benchmarking
• 20.3. Competition Deep Dive
  • 20.3.1. Pfizer Inc.
    • 20.3.1.1. Overview
    • 20.3.1.2. Product Portfolio
    • 20.3.1.3. Sales Footprint
    • 20.3.1.4. Key Financials
    • 20.3.1.5. SWOT Analysis
    • 20.3.1.6. Strategic Overview
  • 20.3.2. Bausch Health Companies Inc
    • 20.3.2.1. Overview
    • 20.3.2.2. Product Portfolio
    • 20.3.2.3. Sales Footprint
    • 20.3.2.4. Key Financials
    • 20.3.2.5. SWOT Analysis
    • 20.3.2.6. Strategic Overview
  • 20.3.3. ANI Pharmaceuticals, Inc.
    • 20.3.3.1. Overview
    • 20.3.3.2. Product Portfolio
    • 20.3.3.3. Sales Footprint
    • 20.3.3.4. Key Financials
    • 20.3.3.5. SWOT Analysis
    • 20.3.3.6. Strategic Overview
  • 20.3.4. Hikma Pharmaceuticals Plc
    • 20.3.4.1. Overview
    • 20.3.4.2. Product Portfolio
    • 20.3.4.3. Sales Footprint
    • 20.3.4.4. Key Financials
    • 20.3.4.5. SWOT Analysis
    • 20.3.4.6. Strategic Overview
  • 20.3.5. Lupin Limited
    • 20.3.5.1. Overview
    • 20.3.5.2. Product Portfolio
    • 20.3.5.3. Sales Footprint
    • 20.3.5.4. Key Financials
    • 20.3.5.5. SWOT Analysis
    • 20.3.5.6. Strategic Overview
  • 20.3.6. Mycovia Pharmaceuticals, Inc.
    • 20.3.6.1. Overview
    • 20.3.6.2. Product Portfolio
    • 20.3.6.3. Sales Footprint
    • 20.3.6.4. Key Financials
    • 20.3.6.5. SWOT Analysis
    • 20.3.6.6. Strategic Overview
  • 20.3.7. Glenmark Pharmaceuticals Limited
    • 20.3.7.1. Overview
    • 20.3.7.2. Product Portfolio
    • 20.3.7.3. Sales Footprint
    • 20.3.7.4. Key Financials
    • 20.3.7.5. SWOT Analysis
    • 20.3.7.6. Strategic Overview
  • 20.3.8. Unique Pharmaceuticals
    • 20.3.8.1. Overview
    • 20.3.8.2. Product Portfolio
    • 20.3.8.3. Sales Footprint
    • 20.3.8.4. Key Financials
    • 20.3.8.5. SWOT Analysis
    • 20.3.8.6. Strategic Overview
  • 20.3.9. PEPTONIC medical AB
    • 20.3.9.1. Overview
    • 20.3.9.2. Product Portfolio
    • 20.3.9.3. Sales Footprint
    • 20.3.9.4. Key Financials
    • 20.3.9.5. SWOT Analysis
    • 20.3.9.6. Strategic Overview
  • 20.3.10. Aurobindo Pharma Limited
    • 20.3.10.1. Overview
    • 20.3.10.2. Product Portfolio
    • 20.3.10.3. Sales Footprint
    • 20.3.10.4. Key Financials
    • 20.3.10.5. SWOT Analysis
    • 20.3.10.6. Strategic Overview
  • 20.3.11. Dr. Reddy's Laboratories
    • 20.3.11.1. Overview
    • 20.3.11.2. Product Portfolio
    • 20.3.11.3. Sales Footprint
    • 20.3.11.4. Key Financials
    • 20.3.11.5. SWOT Analysis
    • 20.3.11.6. Strategic Overview
  • 20.3.12. SCYNEXIS, Inc.
    • 20.3.12.1. Overview
    • 20.3.12.2. Product Portfolio
    • 20.3.12.3. Sales Footprint
    • 20.3.12.4. Key Financials
    • 20.3.12.5. SWOT Analysis
    • 20.3.12.6. Strategic Overview
  • 20.3.13. Basilea Pharmaceutica Ltd.
    • 20.3.13.1. Overview
    • 20.3.13.2. Product Portfolio
    • 20.3.13.3. Sales Footprint
    • 20.3.13.4. Key Financials
    • 20.3.13.5. SWOT Analysis
    • 20.3.13.6. Strategic Overview
  • 20.3.14. Astellas Pharma Inc.
    • 20.3.14.1. Overview
    • 20.3.14.2. Product Portfolio
    • 20.3.14.3. Sales Footprint
    • 20.3.14.4. Key Financials
    • 20.3.14.5. SWOT Analysis
    • 20.3.14.6. Strategic Overview
  • 20.3.15. Grupo Ferrer Internacional, S.A.
    • 20.3.15.1. Overview
    • 20.3.15.2. Product Portfolio
    • 20.3.15.3. Sales Footprint
    • 20.3.15.4. Key Financials
    • 20.3.15.5. SWOT Analysis
    • 20.3.15.6. Strategic Overview
  • 20.3.16. Pacgen Life Science Corporation
    • 20.3.16.1. Overview
    • 20.3.16.2. Product Portfolio
    • 20.3.16.3. Sales Footprint
    • 20.3.16.4. Key Financials
    • 20.3.16.5. SWOT Analysis
    • 20.3.16.6. Strategic Overview
  • 20.3.17. NovaDigm Therapeutics, Inc.
    • 20.3.17.1. Overview
    • 20.3.17.2. Product Portfolio
    • 20.3.17.3. Sales Footprint
    • 20.3.17.4. Key Financials
    • 20.3.17.5. SWOT Analysis
    • 20.3.17.6. Strategic Overview
  • 20.3.18. Cidara Therapeutics, Inc.
    • 20.3.18.1. Overview
    • 20.3.18.2. Product Portfolio
    • 20.3.18.3. Sales Footprint
    • 20.3.18.4. Key Financials
    • 20.3.18.5. SWOT Analysis
    • 20.3.18.6. Strategic Overview
  • 20.3.19. Amplyx Pharmaceuticals Inc.
    • 20.3.19.1. Overview
    • 20.3.19.2. Product Portfolio
    • 20.3.19.3. Sales Footprint
    • 20.3.19.4. Key Financials
    • 20.3.19.5. SWOT Analysis
    • 20.3.19.6. Strategic Overview

21. Assumptions and Acronyms Used

22. Research Methodology

관련자료